Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

EQRX - EQRx, Inc.

Close
2.34
-0.050   -2.137%

Share volume: 0
Last Updated: Wed 08 Nov 2023 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 3.82%

PREVIOUS CLOSE
CHG
CHG%
$2.39
-0.05
-2.09%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$2.34
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
487.696 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO: Melanie I. Nallicheri
Region: US
Website: eqrx.com
Employees: 360
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

EQRx, Inc. engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor, and Sugemalimab, an anti-programmed death-ligand 1 antibody.

Recent news